Inflammatory bowel disease (IBD) and Psoriasis are chronic inflammatory conditions with a shared pathologic process, which explains the use of similar therapeutic strategies. Psoriasis can be associated to IBD as an independent entity, as an extraintestinal manifestation of IBD, or even as a paradoxical event of anti-tumor necrosis factor alpha (TNFa) therapy.  Our main goal was to review our experience of patients treated with TNFa inhibitors regarding the occurrence of psoriasis.